NL-OMON38393已完成3 期
A Phase 3, randomized, double-blind study of the safety and efficacy of GSK1349572 plus abacavir/lamivudine fixed-dose combination therapy administered once daily compared to Atripla over 96 weeks in HIV-1 infected antiretroviral therapy naive adult subjects (ING114467) - ING114467
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •HIV-1 infected subjects >=18 years of age.
- •HIV-1 infection as documented by HIV-1 RNA >400 c/mL.
- •No prior antiretroviral therapy.
- •HLA-B*5701 negative.
- •Safe contraception for women of childbearing potential.
排除标准
- •Breastfeeding, pregnancy.
- •Any evidence of an active CDC Category C disease [CDC, 1993], except cutaneous Kaposi*s sarcoma not requiring systemic therapy or historic or current CD4+ cell count <200 cells/mm3 are not exclusionary.
- •History of malignancy within the past 5 years or ongoing malignancy other than the usual exceptions.
- •Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening.
- •Treatment with any of the following agents within 28 days of Screening: radiation, cytotoxic chemotherapeutic agents, immunomodulators.
研究者
相似试验
进行中（未招募）
不适用
A Phase 3, randomized, double-blind study of the safety and efficacy of GSK1349572 plus abacavir/lamivudine fixed-dose combination therapy administered once daily compared to Atripla over 96 weeks in HIV-1 infected antiretroviral therapy na?ve adult subjects. - SINGLEHIV-1 infected antiretroviral therapy naive adult subjectsMedDRA version: 9.1Level: LLTClassification code 10008922EUCTR2010-020983-39-ITViiV Healthcare UK Limited800
进行中（未招募）
1 期
GSK1349572 plus abacavir/lamivudine fixed-dose combination therapy administered once daily compared to Atripla over 96 weeks in HIV-1 infected adult subjectsHIV-1 infected antiretroviral therapy naive adult subjects.MedDRA version: 14.1Level: LLTClassification code 10008922Term: Chronic infection with HIVSystem Organ Class: 10021881 - Infections and infestationsEUCTR2010-020983-39-DKViiV Healthcare UK Limited800
进行中（未招募）
1 期
A phase 3 clinical trial to compare the safety and effectiveness of GSK1349572 and abacavir/lamivudine compared to Atripla over 96 weeks in patients with HIV infection who have not previously received treatment.EUCTR2010-020983-39-GBViiV Healthcare UK Limited844
进行中（未招募）
不适用
A phase 3 clinical trial to compare the safety and effectiveness of GSK1349572 and abacavir/lamivudine compared to Atripla over 96 weeks in patients with HIV infection who have not previously received treatment.HIV-1 infected antiretroviral therapy naive adult subjects.MedDRA version: 14.1Level: LLTClassification code 10008922Term: Chronic infection with HIVSystem Organ Class: 100000004862EUCTR2010-020983-39-NLViiV Healthcare UK Limited800
进行中（未招募）
1 期
A Phase 3, randomized, double-blind study of the safety and efficacy of GSK1349572 plus abacavir/lamivudine fixed-dose combination therapy administered once daily compared to Atripla over 96 weeks in HIV-1 infected antiretroviral therapy naive adult subjects. - N/AEUCTR2010-020983-39-HUViiV Healthcare UK Limited844